25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
On May 22, 2019, Oregon governor Kate Brown signed House Bill 2341. This bill expands on existing fe...
Read More >
2020 AG Elections -Republican John Westercamp Announces Candidacy for Indiana Attorney General -Jo...
Read More >
Recently, the frequency of stockholder demands to inspect corporate books and records pursuant to Se...
Read More >
In a departure from the federal Americans with Disabilities Act (ADA) and other state anti-discrimin...
Read More >
The Canada Revenue Agency's (CRA) Offshore Tax Informant Program (OTIP) is a whistleblower program t...
Read More >
The 2019 novel coronavirus (COVID-19) pandemic continues to have a significant effect on American li...
Read More >